- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04244526
Urinary Tract Infection in Pregnancy
January 28, 2020 updated by: NSHussein, Assiut University
Distribution of Virulence Genes and Their Association With Clinical Presentation of Urinary Tract Infection and Antimicrobial Resistance Among Uropathogenic Escherichia Coli Isolated From Pregnant Women
- to describe the profile of uropathogenic E coli from Egyptian pregnant women with UTIs and a symptomatic bacteriuria.
- to determine the susceptibility pattern of our local isolated UPEC strains which is essential for optimal management of UTI.
- to evaluate the different virulence genes in UPEC isolates and their association with antibiotic resistance.
- to track common UPEC serogroups.
- to investigate the biofilm formation and the relationship between virulence genes and biofilm formation in UPEC strains isolated from patients.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Urinary tract infection represents the most common bacterial infection in pregnancy and the third common cause of human infection after respiratory and intestinal infections.
The infection can be life threatening and associated with serious complications.
UTI can be associated with defined symptoms'symptomatic' or without symptoms 'asymptomatic'.
Asymptomatic bacteriuria is defined as the presence of >100000 colony forming units/ml of urine of a single pathogen in two consecutive midstream clean catch urine specimen or on catheterization specimen from an individual without signs or symptoms associated with urinary or genital organs.
Asymptomatic bacteriuria can lead to acute pyelonephritis in30%of pregnant women and complications such as early delivery, increase risk of hypertension, pre-eclampsia, low birth weight and postpartum endometritis.
Ecoli accounts for most cases of symptomatic and asymptomatic bacteriuria in women, representing70 _90 %of the cases.
The important virulence factors of uropathogenic ecoli can be broadly divided into two groups :bacterial cell surface factors and secreted factors.
The emergence of drug resistant microorganism among Uropathogenic Escherichia coli strains increases the serious threat to global health.
Ecoli often acquired genes coding for antibiotic resistance, beta-lactamase enzymes are the most frequent and play a key role, conferring resistance of bacteria to beta lactam antibiotic group such as penicillin and cephalosporins.
Therefore, knowledge regarding local prevalence of uropathogenic ecoli and antimicrobial resistance is essential for optimal management of UTI.
Study Type
Observational
Enrollment (Anticipated)
155
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Pregnant women at different trimesters with cystitis and pyelonephritis and asymptomatic bacteriuria
Description
Inclusion Criteria:
- pregnant women who diagnosed through clinical examination and urine analysis. 3 groups : group 1 pregnant women with cystitis Group 2 pregnant women with Pyelonephritis Group 3 pregnant women with asymptomatic bacteriuria
Exclusion Criteria:
- pregnant women on antibiotics _Patients with any anatomical abnormalities in the urinary tract
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Group1
Group 1:pregnant women with cystitis
|
Just taking a urine sample
|
|
Group2
Group 2: pregnant women with Pyelonephritis
|
Just taking a urine sample
|
|
Group3
Group 3: pregnant women with asymptomatic bacteriuria
|
Just taking a urine sample
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The percentage of virulence genes in different isolated UPEC strains
Time Frame: Three months
|
Measurment of virulence genes of Escherichia coli strains by molecular diagnosis as PCR technique to determine relationship between clinical presentation of urinary tract infection and distribution of virulence genes of strains
|
Three months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between the virulence genes and antibiotic resistance
Time Frame: Seven months
|
Measurment of virulence genes of escherichia coli strains by molecular diagnosis as PCR technique,and determine antibiotic susceptibility of ecoli strains between different groups of women to determine relationship between distribution of virulence genea and antibiotic susceptibility of strains
|
Seven months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 1, 2020
Primary Completion (Anticipated)
March 1, 2021
Study Completion (Anticipated)
May 1, 2021
Study Registration Dates
First Submitted
January 25, 2020
First Submitted That Met QC Criteria
January 25, 2020
First Posted (Actual)
January 28, 2020
Study Record Updates
Last Update Posted (Actual)
January 30, 2020
Last Update Submitted That Met QC Criteria
January 28, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Urinary Tract Infection
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Tract Infections
-
GlaxoSmithKlineCompletedInfections, Urinary TractEgypt
-
University of WashingtonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Iterum Therapeutics, International LimitedCompletedComplicated Urinary Tract InfectionsUnited States, Estonia, Hungary, Georgia, Latvia
-
Shandong Branden Med.Device Co.,LtdTerminatedUrinary Tract Infection | Urinary CathetersChina
-
AbbottCompletedUrinary Tract Infections (UTIs)Pakistan
-
Inmunotek S.L.CompletedUrinary Tract Infection BacterialSpain, United Kingdom
-
Omri Schwarztuch GildorEnrolling by invitationUrologic Diseases | Urinary Tract DiseaseIsrael
-
Hamilton Health Sciences CorporationWithdrawnUrinary Tract InfectionCanada
-
US Department of Veterans AffairsCompletedUrinary Tract InfectionUnited States
-
Tufts UniversityCompletedUrinary Tract InfectionUnited States
Clinical Trials on Talking a urine sample
-
Centre Hospitalier Universitaire de NiceRecruiting
-
Universitair Ziekenhuis BrusselCompletedFrailty | Asymptomatic Bacteriuria | Geriatric Syndrome | SIADHBelgium
-
Institute of Tropical Medicine, BelgiumSRI International; Sihanouk Hospital Center of HOPECompletedSystemic Inflammatory Response Syndrome | Melioidosis | Suspected or Confirmed Bloodstream InfectionsCambodia
-
Rennes University HospitalNeuroSphinxRecruiting
-
Institut PasteurCentre Terrritorial Hospitalier Gaston BourretNot yet recruiting
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceRecruitingImmune Thrombocytopenia | Autoimmune Hemolytic Anemia | Autoimmune NeutropeniaFrance
-
University Hospital, ToursCompletedMetastatic Prostate Cancer | Circulating Tumor DNAFrance
-
University Hospital, BordeauxCompletedRenal Function Disorder | Chronic Renal Diseases
-
Masonic Cancer Center, University of MinnesotaNational Institutes of Health (NIH)Withdrawn
-
GlaxoSmithKlineCompletedInfections, StreptococcalBelgium